NASDAQ:AGLE - Aeglea Bio Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$10.72 +0.24 (+2.29 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$10.48
Today's Range$10.05 - $10.82
52-Week Range$2.81 - $12.00
Volume2.01 million shs
Average Volume189,478 shs
Market Capitalization$235.64 million
P/E Ratio-5.96
Dividend YieldN/A
Aeglea Bio Therapeutics logoAeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers. Its preclinical pipeline products comprise AEB3103, an engineered human enzyme that targets the degradation of the amino acid cysteine/cysteine; and AEB2109, an engineered human enzyme that targets the degradation of the amino acid methionine, as well as AEB4104, an engineered human enzyme that targets the reduction of elevated levels of the amino acid homocysteine. Aeglea BioTherapeutics, Inc. has a clinical collaboration agreement with Merck to evaluate the combination of pegzilarginase with Merck's anti-PD1 therapy, pembrolizumab, for the treatment of patients with small cell lung cancer. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

Receive AGLE News and Ratings via Email

Sign-up to receive the latest news and ratings for AGLE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio8.48
Quick Ratio8.48


Trailing P/E Ratio-5.96
Forward P/E Ratio-6.42
P/E GrowthN/A

Sales & Book Value

Annual Sales$5.20 million
Price / Sales45.07
Cash FlowN/A
Price / CashN/A
Book Value$3.02 per share
Price / Book3.55


EPS (Most Recent Fiscal Year)($1.80)
Net Income$-27,230,000.00
Net Margins-507.82%
Return on Equity-54.83%
Return on Assets-49.87%


Outstanding Shares21,860,000

Aeglea Bio Therapeutics (NASDAQ:AGLE) Frequently Asked Questions

What is Aeglea Bio Therapeutics' stock symbol?

Aeglea Bio Therapeutics trades on the NASDAQ under the ticker symbol "AGLE."

How were Aeglea Bio Therapeutics' earnings last quarter?

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) released its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.44) by $0.05. The biotechnology company had revenue of $1.51 million for the quarter. Aeglea Bio Therapeutics had a negative net margin of 507.82% and a negative return on equity of 54.83%. View Aeglea Bio Therapeutics' Earnings History.

What price target have analysts set for AGLE?

3 equities research analysts have issued 12-month price targets for Aeglea Bio Therapeutics' shares. Their predictions range from $20.00 to $37.00. On average, they expect Aeglea Bio Therapeutics' share price to reach $26.00 in the next year. View Analyst Ratings for Aeglea Bio Therapeutics.

Who are some of Aeglea Bio Therapeutics' key competitors?

Who are Aeglea Bio Therapeutics' key executives?

Aeglea Bio Therapeutics' management team includes the folowing people:
  • Dr. Anthony G. Quinn, Interim CEO & Director (Age 56)
  • Prof. George Georgiou Ph.D., Co-Founder and Director (Age 59)
  • Mr. Charles N. York II, M.B.A., Chief Financial Officer and VP (Age 41)
  • Dr. Scott W. Rowlinson Ph.D., VP of Research (Age 50)
  • Dr. Leslie Sloan Ph.D., Sr. VP of Operations

When did Aeglea Bio Therapeutics IPO?

(AGLE) raised $60 million in an initial public offering on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities served as the underwriters for the IPO and Needham & Company was co-manager.

Has Aeglea Bio Therapeutics been receiving favorable news coverage?

Media coverage about AGLE stock has been trending somewhat positive this week, Accern reports. The research group rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Aeglea Bio Therapeutics earned a media sentiment score of 0.03 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 46.20 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Aeglea Bio Therapeutics' major shareholders?

Aeglea Bio Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include NOVARTIS BIOVENTURES LTD (9.80%), Dimensional Fund Advisors LP (0.42%), Millennium Management LLC (0.34%), JPMorgan Chase & Co. (0.30%), Blair William & Co. IL (0.12%) and UBS Group AG (0.11%). Company insiders that own Aeglea Bio Therapeutics stock include Anthony G Quinn, Bioventures Ltd Novartis, Charles N York II and Orbimed Advisors Llc. View Institutional Ownership Trends for Aeglea Bio Therapeutics.

Which institutional investors are buying Aeglea Bio Therapeutics stock?

AGLE stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Dimensional Fund Advisors LP, JPMorgan Chase & Co., UBS Group AG, A.R.T. Advisors LLC, Blair William & Co. IL, Stanley Laman Group Ltd. and Spark Investment Management LLC. Company insiders that have bought Aeglea Bio Therapeutics stock in the last two years include Anthony G Quinn, Charles N York II and Orbimed Advisors Llc. View Insider Buying and Selling for Aeglea Bio Therapeutics.

How do I buy shares of Aeglea Bio Therapeutics?

Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aeglea Bio Therapeutics' stock price today?

One share of AGLE stock can currently be purchased for approximately $10.72.

How big of a company is Aeglea Bio Therapeutics?

Aeglea Bio Therapeutics has a market capitalization of $235.64 million and generates $5.20 million in revenue each year. The biotechnology company earns $-27,230,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Aeglea Bio Therapeutics employs 43 workers across the globe.

How can I contact Aeglea Bio Therapeutics?

Aeglea Bio Therapeutics' mailing address is 901 SOUTH MOPAC EXPRESSWAY BARTON OAKS PLAZA ONE SUITE 250, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-942-2935 or via email at [email protected]

MarketBeat Community Rating for Aeglea Bio Therapeutics (AGLE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  205
MarketBeat's community ratings are surveys of what our community members think about Aeglea Bio Therapeutics and other stocks. Vote "Outperform" if you believe AGLE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGLE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.